Key Summary Points {#FPar1}
==================

Why carry out this study? Multiple biologic drugs are approved for the treatment of moderate-to-severe plaque psoriasis based on efficacy and safety established in phase 3, double-blind, randomized, controlled trials, but direct comparisons of response rates in head-to-head trials are rare, and indirect comparisons using network meta-analyses are limitedWhat was learned from the study? This comprehensive network meta-analysis (NMA) examined a large number of biologics for the treatment of moderate-to-severe psoriasis (adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab, ustekinumab) and focused on higher clinical response rates than previously published NMA investigations We focused specifically on rapid response rates within 12 weeks of treatment because rapid skin clearance and quality of life improvement are important patient preferences in biologic treatment

Introduction {#Sec1}
============

Plaque psoriasis is a chronic, inflammatory skin disease with an estimated prevalence of 1.5--5% in the general population \[[@CR1], [@CR2]\]. Psoriasis significantly impairs patients' quality of life \[[@CR1], [@CR2]\], underscoring the need for timely and effective treatments.

Biologic therapies have transformed the treatment of moderate-to-severe psoriasis and have markedly improved multiple patient outcomes \[[@CR3], [@CR4]\]. Several biologics are available, including inhibitors of interleukin (IL)-17 (brodalumab, ixekizumab, secukinumab), IL-12/-23 (ustekinumab), IL-23 (guselkumab, risankizumab, tildrakizumab), or tumor necrosis factor (adalimumab, certolizumab pegol, etanercept, infliximab) \[[@CR5], [@CR6]\]. These biologics are approved for patients with moderate-to-severe plaque psoriasis based on efficacy and safety established in phase 3, double-blind, randomized, controlled trials (RCTs).

Rapid efficacy is important to patients and clinicians \[[@CR4], [@CR7]--[@CR10]\], but head-to-head comparisons of biologics are rare, and none conducted to date have had speed of onset as a primary objective. We present a comprehensive network meta-analysis (NMA) that indirectly compares rapid response rates at early time points (≤ 12 weeks of treatment) for 11 approved biologics for moderate-to-severe psoriasis. Bayesian and Frequentist NMA (BNMA and fNMA, respectively) were used to investigate Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) response from phase 3 RCTs identified by systematic literature review.

Methods {#Sec2}
=======

Inclusion criteria for the studies with available data to include in the NMA have previously been reported and are listed in Electronic Supplementary Material (ESM) Table 1. These studies included patients who were ≥ 18 years of age with moderate-to-severe psoriasis.

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

PASI 75, PASI 90, and PASI 100 endpoints (≥ 75, ≥ 90, and 100% improvement in PASI score, respectively) were analyzed at weeks 2, 4, 8, and 12, and missing values were handled using nonresponder imputation (NRI) in all studies, with the exception of four studies (CIMPACT \[[@CR11]\], CIMPASI-1 \[[@CR12]\], CIMPASI-2 \[[@CR12]\], CLARITY \[[@CR13]\]) that reported endpoints based on multiple imputation (MI). DLQI (0,1) status, where (0,1) indicates no effect/no impact on patient\'s life, was assessed at week 12, and missing values were handled using NRI in all studies, except for five studies (CIMPASI-1 \[[@CR12]\], CIMPASI-2 \[[@CR12]\], CLARITY \[[@CR13]\], CLEAR \[[@CR14]\], ERASURE \[[@CR15]\]) that used last observation carried forward and one study (FIXTURE \[[@CR15]\]) that did not mention how missing values were treated. When required data were imputed differently (e.g., MI vs. NRI) or analyzed (mixed model for repeated measures vs. analysis of covariance) differently, they were included in the data analysis based on the assumption that the impact of the chosen imputation/analytical method was negligible for treatment effects.

Systematic Literature Review {#Sec3}
----------------------------

Efficacy data on PASI response rates (PASI 75/90/100) at weeks 2, 4, 8, and 12 and DLQI (0,1) response rates at week 12 were obtained from a systematic literature review of the OvidSP platform for literature published since 1 January 1990. The last update search was performed on 12 December 2018. The search parameters were designed to identify publications that reported data from phase 3 RCTs of biologics approved for the treatment of moderate-to-severe psoriasis. Studies included in the NMA are listed in ESM Table 1 \[[@CR11]--[@CR42]\]. The Cochrane Handbook for Systematic Reviews of Interventions guidance was followed \[[@CR43]\].

Outcome Measures Extracted {#Sec4}
--------------------------

We report the relative effects versus placebo for all biologics included in this study, except where data were unavailable. PASI 75/90/100 response data were unavailable at week 2 for risankizumab and tildrakizumab; PASI 100 response data were unavailable at weeks 2, 4, 8, and 12 for certolizumab pegol and infliximab; and DLQI (0,1) response data were unavailable at week 12 for guselkumab, infliximab, and risankizumab.

BNMA used fixed-treatment effect and random-baseline effect, normal independent models \[[@CR44], [@CR45]\]. Convergence for all models was assessed using trace plots as modified by Brooks and Gelman \[[@CR46]\]. Model fit was assessed using the deviance information criterion, and residual deviance (technical model details are given in the ESM). fNMA were conducted as sensitivity analyses to test the robustness of the findings. BNMA were performed in JAGS via R using the R2JAGS package, and fNMA analysis was run using R version 3.4.2 R package with netmeta \[[@CR47]\]. BNMA and fNMA included data from all biologic doses obtained during the systematic literature review (see ESM).

Results {#Sec5}
=======

Based on the BNMA analysis, IL-17 antagonists showed the most rapid treatment effects, with ixekizumab and brodalumab being similar for rapid skin and quality of life responses (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}; Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}).

Ixekizumab and brodalumab showed more rapid treatment effects on PASI 75 response rates at weeks 2, 4, and 8 compared with all other biologics included in the analysis (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}; Table [1](#Tab1){ref-type="table"}). At week 12, ixekizumab and risankizumab had the most rapid treatment effects; the distribution for ixekizumab overlapped with risankizumab, and the distribution for risankizumab overlapped with brodalumab, secukinumab, infliximab, and guselkumab (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}; Table [1](#Tab1){ref-type="table"}).Fig. 1Treatment effects on Psoriasis Area and Severity Index (*PASI*) 75 and PASI 90 response rates (≥ 75 and ≥ 90% improvement in PASI, respectively) at weeks 4, 8, and 12 based on Bayesian Network Meta-Analysis (BNMA). Data are presented as the posterior mean density relative to placebo. On-label doses are represented. *ADA* Adalimumab, *BRO* brodalumab, *CZP* certolizumab pegol, *ETN* etanercept, *GUS* guselkumab, *IFX* infliximab, *IXE* ixekizumab,*RIS* risankizumab, *SEC* secukinumab, *TIL* tildrakizumab, *UST* ustekinumabFig. 2Treatment effects on PASI 75 and PASI 90 response rates at weeks 4, 8, and 12 based on BNMA. Data are presented as the posterior mean and 95% credible interval relative to placebo. Boxes indicate sample size. Ustekinumab is an interleukin (*IL*)-12/-23 inhibitor. On-label doses are represented. *TNFi* Tumor necrosis factor inhibitorTable 1Bayesian network meta-analysis relative treatment effect summary by highest to lowest average rank for Psoriasis Area and Severity Index 75/90/100 response at weeks 2, 4, 8, and 12WeekPASI 75^a^PASI 90^a^PASI 100^a^BiologicTreatment effect relative to PBO (95% CrI)Average rankBiologicTreatment effect relative to PBO (95% CrI)Average rankBiologicTreatment effect relative to PBO (95% CrI)Average rank2BRO0.22 (0.198--0.242)1.165BRO0.05 (0.038--0.060)1.130BRO0.01 (0.004--0.014)1.224IXE0.20 (0.182--0.226)1.835IXE0.04 (0.030--0.051)1.871IXE0.01 (0.001--0.009)2.551IFX0.05 (0.031--0.070)3.314ADA0.01 (− 0.001--0.012)3.846ADA0.01 (− 0.001--0.010)2.821ADA0.03 (0.011--0.055)4.590IFX0.01 (− 0.014--0.023)5.247GUS0 (− 0.003--0.008)4.198CZP0.03 (0.007--0.061)4.608UST0 (− 0.002--0.009)4.830UST0 (0--0)5.731UST0.02 (0.003--0.029)6.429GUS0 (− 0.001--0.001)6.864ETN0 (0--0)5.736GUS0.02 (− 0.003--0.037)6.480ETN0 (0--0)7.066SEC0 (0--0)5.738ETN0.01 (0.002--0.014)7.646SEC0 (0--0)7.072--SEC0 (0--0)8.934CZP0 (0--0)7.074--4BRO0.58 (0.553--0.606)1.007BRO0.29 (0.261--0.308)1.001BRO0.09 (0.071--0.100)1.100IXE0.53 (0.506--0.559)1.993IXE0.24 (0.214--0.257)2.001IXE0.07 (0.060--0.086)1.900SEC0.37 (0.337--0.402)3.007IFX0.16 (0.112--0.206)3.136TIL0.01 (0--0.016)3.465IFX0.30 (0.261--0.344)4.010SEC0.13 (0.113--0.149)3.862RIS0.01 (0--0.012)3.792RIS0.24 (0.199--0.280)5.130RIS0.06 (0.041--0.079)5.065UST0 (0--0)6.941GUS0.21 (0.164--0.249)6.006ADA0.04 (0.029--0.053)6.261ADA0 (0--0)6.946ADA0.18 (0.160--0.207)6.861GUS0.03 (0.014--0.043)8.205GUS0 (0--0)6.952CZP0.13 (0.090--0.168)8.604UST0.03 (0.016--0.040)8.334ETN0 (0--0)6.949UST0.13 (0.100--0.149)8.715CZP0.03 (0.007--0.046)8.543SEC0 (0--0)6.955TIL0.11 (0.076--0.134)9.716TIL0.03 (0.008--0.042)8.799--ETN0.08 (0.063--0.092)10.952ETN0.01 (0.006--0.019)10.794--8IXE0.79 (0.766--0.811)1.048BRO0.59 (0.560--0.613)1.152BRO0.30 (0.274--0.321)1.001BRO0.76 (0.735--0.784)1.953IXE0.57 (0.542--0.593)1.848IXE0.25 (0.225--0.270)1.999SEC0.69 (0.655--0.719)3.365SEC0.44 (0.406--0.467)3.947SEC0.17 (0.142--0.193)3.105RIS0.67 (0.618--0.712)4.300IFX0.44 (0.374--0.497)3.991RIS0.14 (0.114--0.173)3.900IFX0.65 (0.612--0.697)4.756RIS0.43 (0.387--0.479)4.066GUS0.09 (0.066--0.118)5.292GUS0.63 (0.584--0.677)5.578GUS0.34 (0.297--0.372)5.996UST0.08 (0.062--0.099)5.975ADA0.52 (0.487--0.547)7.178UST0.25 (0.216--0.274)7.310ADA0.07 (0.051--0.081)7.226UST0.50 (0.463--0.527)7.910ADA0.23 (0.193--0.270)7.806TIL0.06 (0.041--0.082)7.502CZP0.45 (0.386--0.504)9.015TIL0.20 (0.163--0.230)8.995ETN0.02 (0.010--0.029)9.000TIL0.40 (0.354--0.442)9.897CZP0.16 (0.125--0.203)9.889--ETN0.30 (0.276--0.321)11.000ETN0.10 (0.079--0.111)10.999--12IXE0.85 (0.825--0.866)1.019IXE0.70 (0.671--0.720)1.099BRO0.40 (0.375--0.426)1.182RIS0.80 (0.752--0.839)2.650BRO0.67 (0.647--0.698)1.929IXE0.38 (0.359--0.408)1.819BRO0.79 (0.767--0.814)2.710RIS0.62 (0.577--0.665)3.173RIS0.31 (0.267--0.344)3.248SEC0.76 (0.740--0.789)4.334SEC0.59 (0.558--0.615)4.262SEC0.29 (0.262--0.316)3.752IFX0.75 (0.715--0.793)4.981IFX0.57 (0.511--0.634)4.730GUS0.21 (0.177--0.248)5.003GUS0.75 (0.719--0.782)5.307GUS0.54 (0.501--0.576)5.806UST0.16 (0.143--0.173)6.038ADA0.63 (0.604--0.662)7.682UST0.42 (0.395--0.453)7.011ADA0.13 (0.114--0.152)7.285UST0.63 (0.604--0.658)7.790ADA0.37 (0.343--0.399)8.374TIL0.12 (0.096--0.152)7.674CZP0.61 (0.548--0.665)8.722TIL0.35 (0.308--0.390)9.253ETN0.05 (0.040--0.064)9.000TIL0.57 (0.526--0.616)9.806CZP0.34 (0.293--0.396)9.363--ETN0.44 (0.420--0.468)11.000ETN0.21 (0.189--0.228)11.000--On-label doses are representedDashes indicate that data were unavailable*ADA* adalimumab, *BRO* brodalumab, *CrI* credible interval, *CZP* certolizumab pegol, *ETN* etanercept, *GUS* guselkumab, *IFX* infliximab, *IXE* ixekizumab, *PBO* placebo, *RIS* risankizumab, *SEC* secukinumab, *TIL* tildrakizumab, *UST* ustekinumab^a^Psoriasis Area and Severity Index (PASI). PASI 75, 90, and 100 endpoints represent ≥ 75, ≥ 90, and 100% improvement in PASI score, respectively, from baseline

Similarly, ixekizumab and brodalumab showed more rapid treatment effects on PASI 90 response rates at weeks 2, 4, 8, and 12 than did all of the other biologics included in the analysis (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}; Table [1](#Tab1){ref-type="table"}). Ixekizumab and brodalumab had the most rapid treatment effects at week 2, brodalumab had the most rapid treatment effects at week 4, and ixekizumab and brodalumab had the most rapid treatment effects at weeks 8 and 12 where distributions overlapped (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}; Table [1](#Tab1){ref-type="table"}). Ixekizumab and brodalumab had no overlap but were followed at week 4 by infliximab and secukinumab and at week 8 by secukinumab, infliximab, and risankizumab, and distributions did overlap for those treatments. At week 12, distributions for ixekizumab and brodalumab overlapped, and the distribution for brodalumab overlapped with risankizumab, which in turn overlapped with secukinumab and infliximab (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}; Table [1](#Tab1){ref-type="table"}).

Ixekizumab and brodalumab showed the most rapid treatment effects for PASI 100 at weeks 4 and 12, and brodalumab showed the most rapid treatment effects at week 8 (Table [1](#Tab1){ref-type="table"}; ESM Figs. 1, 2).

Average (i.e., posterior mean) relative treatment effect was greatest for ixekizumab, brodalumab, and secukinumab on the DLQI (0,1) response rates at week 12, where distributions overlapped for these three treatments (Fig. [3](#Fig3){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}).Fig. 3Treatment effects on the Dermatology Life Quality Index (DLQI) (0,1) response rates at week 12 based on BNMA. Score (0,1) indicates no effect on patient. Data are presented as the posterior mean density relative to placebo. Guselkumab and infliximab data were not available at week 12. Ustekinumab is an IL-12/-23 inhibitor. On-label doses are representedTable 2Bayesian network meta-analysis relative treatment effect summary by highest to lowest average rank for the Dermatology Life Quality Index (0,1) response at week 12DLQI (0,1) response at week 12BiologicTreatment effect relative to PBO (95% CrI)Average rankIXE0.57 (0.533--0.612)1.207BRO0.55 (0.517--0.576)2.120SEC0.53 (0.497--0.567)2.680UST0.45 (0.423--0.474)4.209CZP0.41 (0.324--0.497)4.892TIL0.35 (0.300--0.393)5.942ETN0.30 (0.269--0.330)6.953ADA0.18 (0.101--0.260)7.997On-label doses are represented*DLQI (0,1)* Dermatology Life Quality Index (0,1)

Results from fNMA were consistent with those from BNMA, with similar treatment rankings for PASI 75/90/100 at weeks 2, 4, 8, and 12 and for DLQI (0,1) at week 12. PASI 90 at week 12 rankings are presented (Table [3](#Tab3){ref-type="table"}). Ixekizumab and brodalumab were ranked highest compared with the other biologics included in the fNMA analysis. Network diagrams are presented for PASI 90 at week 12 (Fig. [4](#Fig4){ref-type="fig"}). In Fig. [4](#Fig4){ref-type="fig"}, lines represent direct comparisons using RCTs, and numbers represent the number of RCTs included in each comparison.Table 3Frequentist network meta-analysis treatment rankings for Psoriasis Area and Severity Index 90 response rates at week 12BiologicTreatment effect relative to PBO (95% CI)Rank (*P* score)IXE0.70 (0.671--0.720)0.995BRO0.67 (0.647--0.698)0.951RIS0.62 (0.577--0.665)0.865SEC0.59 (0.557--0.614)0.780IFX0.57 (0.511--0.633)0.756GUS0.54 (0.502--0.577)0.695UST0.42 (0.395--0.453)0.526ADA0.37 (0.344--0.400)0.359TIL0.35 (0.308--0.390)0.287CZP0.34 (0.284--0.391)0.257ETN0.21 (0.188--0.227)0.105On-label doses are representedFig. 4PASI 90 network diagram at week 12. A total of 33 studies and 20 treatments are included. On- and off-label doses are represented. Lines represent direct comparisons using randomized, controlled trials (RCTs); numbers represent the number of RCTs included in each comparison; network diagrams are the same for both BNMA and frequentist network meta-analysis. *Q2W* Every 2 weeks, *Q4W* every 4 weeks

Discussion {#Sec6}
==========

In this comprehensive NMA of phase 3 RCTs, ixekizumab and brodalumab provided the most rapid and highest clinical response of PASI 75, PASI 90, or PASI 100 as early as week 2 compared to other biologic treatments (secukinumab, ustekinumab, guselkumab, adalimumab, and etanercept). DLQI (0,1) response rate distributions at week 12 overlapped for ixekizumab, brodalumab, and secukinumab. BNMA and fNMA results showed similar relative effect estimates with comparable treatment rankings. These findings align with previously published reports of rapid clinical improvement for patients with moderate-to-severe psoriasis treated with ixekizumab or brodalumab \[[@CR48]--[@CR50]\].

Rapid improvements in skin and the ability to feel better quickly are important treatment attributes of a psoriasis therapy. These are important patient preferences for treatments and are ranked among the highest desired priorities in multiple reports \[[@CR2], [@CR4], [@CR9], [@CR10], [@CR51], [@CR52]\]. However, rapid effect is also tied to longer-term outcomes, including skin improvement, quality of life, and reduction in itch \[[@CR50], [@CR53]--[@CR55]\], though it must be noted that an association between rapid effect and long-term outcomes was not assessed in this analysis. It is also important to note that each patient has different treatment expectations \[[@CR51], [@CR56]\] and that the alignment of individual patient needs with physician goals may improve adherence and satisfaction with therapy \[[@CR56]\].

Several limitations to this study should be considered. NMA differs from a traditional meta-analysis in that it is not an analysis of only head-to-head studies of the same intervention with the same comparator. NMA relies on a network of evidence from RCTs where relevant treatments are connected by trials, and this provides a combination of direct and indirect comparisons for analysis of the comparative effects of many interventions \[[@CR57]\]. RCTs are considered to be the gold standard for treatment comparisons and provide valuable clinical data, and the studies included in the analyses are assumed to be generally similar and consistent; however, heterogeneity still may exist. There may be clinical differences (participants, populations \[naïve versus experienced\], duration of follow-up, and mode of administration) and methodological differences (study design, approaches to analysis, and imputation methods) that may not be aligned due to the availability of or clarity in the published data. For example, an insufficient number of RCTs included in this analysis had DLQI (0,1) response rates available at time points earlier than week 12; the threshold for NMA inclusion was not met and, thus, earlier quality of life response was not evaluated. This may contribute to selection and reporting bias. The way endpoints were imputed was clear in the majority of studies included in the analysis; however, the imputation method used for DLQI (0,1) missing values was not mentioned in one study (FIXTURE \[[@CR15]\]). Another important caveat is that quality of life was limited in this report by what the DLQI tool could capture in the narrow RCT population. Our focus was limited to the first 12 weeks of treatment, and as such, long-term quality of life impacts of psoriasis and costs associated with disease management were not examined. Safety and patient-reported outcomes data, including those related to quality of life, were not examined in this report. The NMA results presented here are not direct comparisons and should be interpreted with caution if used to inform future treatment choices. Finally, results cannot be generalized by class because not all members of the IL-17 superfamily of cytokines were shown to be rapid in this analysis and there was some overlap between these and members of different classes, such as IL-23.

Conclusions {#Sec7}
===========

Overall, this NMA demonstrates that ixekizumab and brodalumab provide the most rapid skin clearance and quality of life improvement within 12 weeks compared with other leading biologic treatments for patients with moderate-to-severe psoriasis, including secukinumab, an IL-17 antagonist, and biologics that inhibit the IL-12/-23, IL-23, or TNF pathways.
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